STEHLÍKOVÁ, Olga, Jana CHOVANCOVÁ, Boris TICHÝ, Marta KREJČÍ, Yvona BRYCHTOVÁ, Anna PANOVSKÁ, Hana SKUHROVÁ FRANCOVÁ, Kateřina BURČKOVÁ, Marek BORSKÝ, Tomáš LOJA, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michael DOUBEK. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. International Journal of Laboratory Hematology. Hoboken (USA): Blackwell Scientific Publications, 2014, vol. 36, No 2, p. 165-171. ISSN 1751-5521. doi:10.1111/ijlh.12149.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
Authors STEHLÍKOVÁ, Olga (203 Czech Republic, belonging to the institution), Jana CHOVANCOVÁ (203 Czech Republic, belonging to the institution), Boris TICHÝ (203 Czech Republic, belonging to the institution), Marta KREJČÍ (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Anna PANOVSKÁ (203 Czech Republic, belonging to the institution), Hana SKUHROVÁ FRANCOVÁ (203 Czech Republic, belonging to the institution), Kateřina BURČKOVÁ (203 Czech Republic, belonging to the institution), Marek BORSKÝ (203 Czech Republic, belonging to the institution), Tomáš LOJA (703 Slovakia, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution) and Michael DOUBEK (203 Czech Republic, belonging to the institution).
Edition International Journal of Laboratory Hematology, Hoboken (USA), Blackwell Scientific Publications, 2014, 1751-5521.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 1.819
RIV identification code RIV/00216224:14740/14:00074835
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1111/ijlh.12149
UT WoS 000332777000008
Keywords in English CELL; CLL; FLUDARABINE; DIAGNOSIS; SURVIVAL; TRIAL
Tags EL OK, kontrola MP, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Martina Prášilová, učo 342282. Changed: 28. 4. 2015 10:59.
Abstract
Introduction Minimal residual disease (MRD) detection has become increasingly important for the assessment of therapy response in chronic lymphocytic leukemia (CLL). However, current MRD analysis methods, both molecular genetic and flow cytometric, are time-consuming and require experienced laboratory staff. Methods To reduce the demands of flow cytometric MRD detection in CLL, we have introduced a novel flow cytometric 8-color protocol. The MRD analysis results using this protocol were then compared with the commonly employed 4-color protocol and the molecular genetic (real-time quantitative allele-specific oligonucleotide IGH polymerase chain reaction; RQ-ASO IGH PCR) approach. Results Forty-two CLL patient samples were repeatedly analyzed after allogeneic stem cell transplantation (n=20) or after fludarabine-based therapy (n=22), and 100% concordance was found using both flow cytometric protocols. Furthermore, there was a strong correlation (r=0.94) between flow cytometric and RQ-ASO IGH PCR results in MRD detection. Conclusion Flow cytometry is less time-consuming, less financially demanding, and moreover, MRD assessment using our novel 8-color protocol is less complicated than the 4-color approach and molecular methods.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
EE2.3.20.0045, research and development projectName: Podpora profesního růstu a mezinárodní integrace výzkumných týmů v oblasti molekulární medicíny
MSM0021622430, plan (intention)Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie
Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies
MUNI/A/0723/2012, interní kód MUName: Nové klinické a diagnostické přístupy u hematogických malignit (Acronym: NoKliDiPřiHeMa)
Investor: Masaryk University, Category A
NT13493, research and development projectName: Molekulární charakterizace B buněčných receptorů a jejich vztah k evoluci genetických změn u chronické lymfocytární leukémie
7E13008, research and development projectName: Next Generation Sequencing Platform for Targeted Personalized Therapy of Leukemia (Acronym: NGS-PTL)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 26. 6. 2022 09:51